Rebounding from a disappointing IPO, Israel’s NeuroDerm watched its shares more than double on promising results from a small study of its Parkinson’s disease treatments. …read more Source: NeuroDerm soars on promising Parkinson’s results
Spark Therapeutics jumped into existence late in 2013 with a pipeline of gene therapy projects spawned by investigators at the Children’s Hospital of Philadelphia and quickly followed up this year with a $73 million round, breakthrough drug status and a $280 million partnership with Pfizer. Now it’s ending its freshman year by filing to go […]
Flex Pharma, founded by serial biotech entrepreneur Christoph Westphal, is lining up for an IPO less than a year after its launch, angling to raise $60 million to bankroll its work in muscle disorders. …read more Source: Westphal’s Flex Pharma swings for a quick $60M IPO
Back in the summer of 2013, Celgene lined up with a group of stalwarts to pump $33 million into the struggling regenerative medicine company Tengion, which had two programs in early-stage development. Today, the biotech powerhouse was listed as a creditor on an international roster of R&D groups and support companies that are getting stiffed […]
Eight months after OncoGenex Pharmaceuticals and Teva acknowledged that their experimental cancer drug custirsen had flopped in a Phase III prostate cancer study, the big Israeli pharma company has executed a strategic retreat from their partnership. Teva is handing over $27 million to OncoGenex to complete the divorce and is walking away from a deal […]
Here’s a perennial favorite among the top trends in the industry. About six years ago, most of Big Pharma got serious about one of its biggest problems: they were really, really bad at drug development. …read more Source: Approvals aren’t enough; Big Pharma R&D restructuring will continue
The billions of dollars raised on the market in IPOs and secondary offerings has been bankrolling an expanding amount of development work at companies around the world. For biotech, these are the days. …read more Source: Will a 2-year IPO boom continue into 2015? Maybe so, with caveats
After years of posting impressive clinical results and pushing analyst projections to greater and greater heights, a new class of cancer treatments has finally made its way onto the market, opening up what’s expected to become a multibillion-dollar industry. …read more Source: A new era of immuno-oncology has arrived
The world of gene therapy–in which single-dose treatments correct debilitating defects–enjoyed something of a renaissance in 2014. Strong clinical results from leaders in the once-maligned field spurred renewed optimism, helping a new generation of startups secure millions in venture financing to develop their next-generation approaches to the field. …read more Source: ‘Futuristic’ treatments come to […]
In the coming year, you can expect to see a lot more work being done on Asian deals, particularly for China. Through the course of this past year there have been growing signs of this global evolution. …read more Source: Biotech goes global as Asia gets connected with the U.S. and Europe
